Published in Eur J Nucl Med on September 01, 1993
Atomic-level accuracy in simulations of large protein crystals. Proc Natl Acad Sci U S A (1994) 1.24
Secondary structure and NMR assignments of Bacillus circulans xylanase. Protein Sci (1996) 0.90
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet (1996) 2.23
Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol (1994) 2.11
Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol (2004) 2.09
Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med (1996) 1.99
Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol (1998) 1.94
Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. BMJ (1988) 1.89
Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol (1992) 1.74
Bone densitometry: current status and future prospects. Br J Radiol (1997) 1.57
Periprosthetic bone remodelling of two types of uncemented femoral implant with proximal hydroxyapatite coating: a 3-year follow-up study addressing the influence of prosthesis design and preoperative bone density on periprosthetic bone loss. Osteoporos Int (2003) 1.56
Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density. Am J Transplant (2006) 1.51
Contact quantitative ultrasound: an evaluation of precision, fracture discrimination, age-related bone loss and applicability of the WHO criteria. Osteoporos Int (1999) 1.51
Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med (2001) 1.49
1alpha-hydroxyvitamin D3 in primary hyperparathyroidism. Clin Endocrinol (Oxf) (1977) 1.48
Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation. Calcif Tissue Int (2010) 1.48
Individual kidney function in atherosclerotic nephropathy is not related to the presence of renal artery stenosis. Nephrol Dial Transplant (1999) 1.46
Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet (1984) 1.45
Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med (1988) 1.44
Occupational dose to the radiographer in dual X-ray absorptiometry: a comparison of pencil-beam and fan-beam systems. Br J Radiol (1996) 1.41
Ablation of mediastinal parathyroid adenomas by superselective embolization of the internal mammary artery with alcohol. Clin Radiol (1993) 1.39
1, 2, 3, or 4 phase bone imaging--how many are necessary? Nucl Med Commun (1990) 1.39
The role of nuclear medicine in orthopaedics. Nucl Med Commun (1994) 1.39
Absorption of oral diphosphonate in normal subjects. Clin Endocrinol (Oxf) (1986) 1.38
Hypercalcaemia of malignancy: evidence for a nonparathyroid humoral agent with an effect on renal tubular handling of calcium. Clin Sci (Lond) (1984) 1.36
Visual assessment of vertebral deformity by X-ray absorptiometry: a highly predictive method to exclude vertebral deformity. Osteoporos Int (2000) 1.30
The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med (1978) 1.30
Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound? Osteoporos Int (2000) 1.25
Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med (1999) 1.24
Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med (1986) 1.20
A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer (1997) 1.20
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer (2003) 1.20
Chronic low back pain: comparison of bone SPECT with radiography and CT. Radiology (1992) 1.18
Hypercalcaemia and metastatic bone disease: is there a causal link? Lancet (1982) 1.15
A clinical profile of back pain and disability in patients with spinal osteoporosis. Bone (1994) 1.14
Analysis of IL-2, IL-4, and IFN-gamma-producing cells in situ during immune responses to protein antigens. J Immunol (1993) 1.13
Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int (2012) 1.13
Technical principles of dual energy x-ray absorptiometry. Semin Nucl Med (1997) 1.12
The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med (2001) 1.12
16-detector multislice CT: dosimetry estimation by TLD measurement compared with Monte Carlo simulation. Br J Radiol (2004) 1.11
Bone mineral measurements in clinical practice. Br J Hosp Med (1987) 1.11
The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am J Obstet Gynecol (1990) 1.10
Fluorine-18-FDG PET in Paget's disease of bone. J Nucl Med (1997) 1.10
Management of male osteoporosis: report of the UK Consensus Group. QJM (1998) 1.10
The role of positron emission tomography in the management of bone metastases. Cancer (2000) 1.10
The value of SPECT scans in identifying back pain likely to benefit from facet joint injection. Br J Rheumatol (1996) 1.09
Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis. J Bone Miner Res (2001) 1.08
Hypercalcaemic osteomalacia due to aluminium toxicity. Lancet (1982) 1.08
Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int (2009) 1.08
Reappraisal of the baseline bone scan in breast cancer. J Nucl Med (1988) 1.07
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int (2003) 1.07
Biochemical prediction of response of bone metastases to treatment. Br J Cancer (1988) 1.07
Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics (1989) 1.06
Oral surgery: ARONJ masterclass. Br Dent J (2014) 1.06
Inheritance of isozyme variation and heterozygosity in Pinus ponderosa. Biochem Genet (1979) 1.06
Morphometric X-ray absorptiometry and morphometric radiography of the spine: a comparison of prevalent vertebral deformity identification. J Bone Miner Res (2000) 1.06
Estimation of skeletal involvement in primary hyperparathyroidism. Use of 24-hour whole-body retention of technetium-99m diphosphonate. Ann Intern Med (1980) 1.05
Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J (Clin Res Ed) (1984) 1.05
Dual energy x-ray absorptiometry: the effects of beam hardening on bone density measurements. Med Phys (1992) 1.05
The role of positron emission tomography in skeletal disease. Semin Nucl Med (2001) 1.04
Non-invasive assessment of skeletal kinetics using fluorine-18 fluoride positron emission tomography: evaluation of image and population-derived arterial input functions. Eur J Nucl Med (1999) 1.04
'Sink or swim': an evaluation of the clinical characteristics of individuals with high bone mass. Osteoporos Int (2011) 1.03
Effect of increasing vertebral marrow fat content on BMD measurement, T-Score status and fracture risk prediction by DXA. Bone (2008) 1.02
Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int (2000) 1.02
Too much heparin: possible source of error in blood gas analysis. Br Med J (Clin Res Ed) (1983) 1.02
Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol (1988) 1.02
Fractal analysis of trabecular bone in knee osteoarthritis (OA) is a more sensitive marker of disease status than bone mineral density (BMD). Calcif Tissue Int (2005) 1.01
Vitamin D and bone mineral density. Osteoporos Int (1998) 0.99
Radiation exposure in bone mineral density assessment. Appl Radiat Isot (1999) 0.99
Extra-articular features of benign joint hypermobility syndrome. Br J Rheumatol (1996) 0.99
Fractal signature analysis of macroradiographs measures trabecular organization in lumbar vertebrae of postmenopausal women. Calcif Tissue Int (1994) 0.99
Bone scintigraphy in benign bone disease. Br Med J (Clin Res Ed) (1984) 0.99
Bone mineral density in professional female dancers. Br J Sports Med (1997) 0.98
The role of bone scanning in osteomalacia. J Nucl Med (1978) 0.97
Quantification of skeletal kinetic indices in Paget's disease using dynamic 18F-fluoride positron emission tomography. J Bone Miner Res (2002) 0.97
Diagnosis of deep-vein thrombosis: comparison of clinical evaluation, ultrasound, plethysmography, and venoscan with X-ray venogram. Lancet (1984) 0.97
Comparison of clinical, radionuclide, and radiographic features of osteoarthritis of the hands. Ann Rheum Dis (1991) 0.97
Frequencies of null alleles at enzyme Loci in natural populations of ponderosa and red pine. Genetics (1982) 0.97
Different approaches to bone densitometry. J Nucl Med (2000) 0.96
Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet (1995) 0.96
Clinical value of adrenal androgen measurement in the diagnosis of delayed puberty. Lancet (1981) 0.95
A low dose regime of 1 alpha hydroxyvitamin D3 in the management of senile osteoporosis: a pilot study. Clin Endocrinol (Oxf) (1980) 0.95
The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am J Med (1997) 0.95
Bone scintigraphy in metabolic bone disease. Semin Nucl Med (1997) 0.95
The value of bone scintigraphy in the evaluation of osteoporotic patients with back pain. Scand J Rheumatol (2002) 0.94
The effect of season and vitamin D supplementation on bone mineral density in healthy women: a double-masked crossover study. Osteoporos Int (2001) 0.94
The effect of vertebral collapse on spinal bone mineral density measurements in osteoporosis. Bone Miner (1992) 0.93